To appraise the clinical and cost-effectiveness of Venetoclax in combination with azacitidine within its marketing authorisation for acute myelogenous leukaemia
 
Status Proposed
Process STA 2018
ID number 1564

Provisional Schedule

Expected publication 22 September 2021

Project Team

Project lead Louise Jafferally

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
17 September 2020 - 08 October 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
17 September 2020 The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of Venetoclax with a hypomethylating agent or low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable For information, this appraisal has been rescheduled to allow the company to include important data to be presented in their submission. Therefore, this appraisal will be removed from the NICE’s reporting targets for timelines and the company accepts that this drug will not be eligible to receive interim CDF funding from the date of marketing authorisation. The appraisal is now anticipated to begin during late October 2020 when we will write to you about how you can get involved.
17 September 2020 Proposed. Topic is in progress
18 March 2020 The Department for Health and Social Care has asked NICE to conduct an appraisal of venetoclax with a hypomethylating agent or low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable. Following advice received from the company, the timelines for this appraisal are currently to be confirmed. A further update on timelines will be available in due course.
21 June 2019 As you will be aware, the Department for Health and Social Care has asked NICE to conduct an appraisal of venetoclax with a hypomethylating agent or low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable. Please note that following on from advice received from the company the timelines for this appraisal have been revised. We now anticipate that the appraisal will begin during mid- March 2020 when we will write to you about how you can get involved.
25 April 2019 - 24 May 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
09 May 2019 In progress. Referred 31 July 2017

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance